Navigation Links
PTC Therapeutics To Present At The J.P. Morgan Healthcare Conference
Date:1/6/2014

SOUTH PLAINFIELD, N.J., Jan. 6, 2014 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will present a company overview at the 2014 J.P. Morgan Healthcare Conference on Monday, January 13 at 3:00 pm PT.

(Logo:  http://photos.prnewswire.com/prnh/20010919/PTCLOGO)

The presentation will be webcast live on the Events and Presentations page under the investor relations section of PTC Therapeutics' website at www.ptcbio.com. The presentation will be archived for two weeks following the presentation. It is recommended that users connect to PTC's website several minutes prior to the start of the webcast to ensure a timely connection.

ABOUT PTC THERAPEUTICS, INC.

PTC is biopharmaceutical company focused on the discovery and development of orally administered, proprietary small molecule drugs that target post-transcriptional control processes. Post-transcriptional control processes regulate the rate and timing of protein production and are essential to proper cellular function. PTC's internally discovered pipeline addresses multiple therapeutic areas, including rare disorders, oncology and infectious diseases. PTC has developed proprietary technologies that it applies in its drug discovery activities and which form the basis for collaborations with leading biopharmaceutical companies. For more information on the company, please visit our website www.ptcbio.com.

FORWARD LOOKING STATEMENTS:

Any statements in this press release about future expectations, plans and prospects for PTC, the development of and potential market for our product candidates, and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan" "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Forward-looking statements involve substantial risks and uncertainties that could cause our future results, performance or achievements to differ significantly from those expressed or implied by these forward-looking statements. Such risks and uncertainties include, among others, those related to the initiation and conduct of clinical trials, availability of data from clinical trials, expectations for regulatory approvals, our scientific approach and general development progress, the availability or commercial potential of our product candidates and other factors discussed in the "Risk Factors" in the most recent Quarterly Report, which is on file with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent our views only as of the date of this release. We anticipate that subsequent events and developments will cause the our views to change. However, while PTC may elect to update these forward-looking statements at some point in the future, we specifically disclaim any obligation to do so. These forward-looking statements should not be relied upon as representing PTC's views as of any date subsequent to the date of this press release.


'/>"/>
SOURCE PTC Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
2. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
3. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
4. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
5. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
6. Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland
7. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
8. Cara Therapeutics Licenses Novel Kappa Opioid Agonist, CR845, to Chong Kun Dang Pharmaceutical Corporation For South Korean Market
9. Frost & Sullivan: High Uptake of New Drug Therapies and Aging Population Expansion Keep the U.S. Retinal Therapeutics Market Buoyant
10. Zenobia Therapeutics, Inc. And BioBlocks, Inc. Announce Sale Of A Joint Fragment Library Ideal For Screening By All Popular Methods
11. New Forecast Shows Global Protein Therapeutics Market to Reach $143.4 Billion by 2015
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... May 3, 2016  While you may be familiar with watching a film or TV show ... as ultra-high-definition or 8MP in the Medical Industry.  Ampronix  is a renowned authorized reseller of ... Photo - http://photos.prnewswire.com/prnh/20160502/362730 ... ... ...
(Date:5/3/2016)... DUBLIN , May 3, 2016 ... to pay $55 million to a woman who says ... State court awarded Gloria Ristesund $5 million ...      (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , ... of accusations against the company. In February, the same ...
(Date:5/3/2016)... May 3, 2016 Intec Pharma ... clinical-stage biopharmaceutical company, today announced the appointment of ... Affairs. "Ms. Strauss-Levy has 15 years of ... established an outstanding track record, having supported the advancement ... approval processes in the United States ...
Breaking Medicine Technology:
(Date:5/3/2016)... ON (PRWEB) , ... May 03, 2016 , ... ... recognized as one of Canada’s top Information and Communication Technology (ICT) companies in ... Canadian and Multinational ICT companies operating in Canada, as ranked by revenue. ...
(Date:5/3/2016)... CA (PRWEB) , ... May 03, 2016 , ... ... a special type of surgical procedure that can be used to diagnose and treat ... instruments can be inserted. These instruments include a special lighting system and lens that ...
(Date:5/3/2016)... ... May 03, 2016 , ... ... connectivity solutions, today announced the new SecureAccess feature for its CelestixEdge solution. ... SecureAccess release will enable organizations to get the DirectAccess user experience on ...
(Date:5/3/2016)... ... ... LunchSkins is changing the future of ocean plastic pollution by launching ... baggies. The mission-driven bags give back to global leaders in the fight to end ... is all about reducing global plastic waste and we’ve teamed up with some powerful ...
(Date:5/3/2016)... (PRWEB) , ... May 03, ... ... Carnival Cruise Lines premiered the state-of-the-art Carnival Vista – the line’s largest ... ship, The Cruise Web has created an infographic spotlighting the Carnival ...
Breaking Medicine News(10 mins):